Procept Biorobotics Corp (PRCT)

Currency in USD
49.96
+1.45(+2.99%)
Closed·
After Hours
50.95+0.99(+1.98%)
·
PRCT Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
PRCT is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
47.1349.99
52 wk Range
47.04103.81
Key Statistics
Prev. Close
48.51
Open
48
Day's Range
47.13-49.99
52 wk Range
47.04-103.81
Volume
1.28M
Average Volume (3m)
928.29K
1-Year Change
-19.42%
Book Value / Share
7.1
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
PRCT Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
75.78
Upside
+51.68%
Members' Sentiments
Bearish
Bullish
ProTips
Stock has taken a big hit over the last week

Procept Biorobotics Corp News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Sell
Moving Averages
Sell

Procept Biorobotics Corp Company Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. It also provides HYDROS Robotic System, which provides Aquablation therapy image-guided robotic therapy to treat males suffering from lower urinary tract symptoms due to benign prostatic hyperplasia. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.

Procept Biorobotics Corp Earnings Call Summary for Q1/2025

  • Procept Biorobotics beats Q1 2025 EPS forecast with -$0.45 vs -$0.4907 expected; revenue reaches $69.2M, exceeding $65.43M estimate
  • Total revenue up 55% YoY; U.S. revenue grows 50% to $60.3M; gross margin improves 7.5 points to 63.9%
  • Full-year revenue guidance set at $323M, up 44% YoY; plans to sell 210 new robotic systems in 2025
  • Stock rises 0.92% in pre-market trading; analysts maintain strong buy consensus with 1.6 rating
  • Company expands internationally in UK and Japan; receives FDA IDEA approval for prostate cancer trial
Last Updated: 24/04/2025, 14:36
Read Full Transcript

Compare PRCT to Peers and Sector

Metrics to compare
PRCT
Peers
Sector
Relationship
P/E Ratio
−30.6x−3.8x−0.5x
PEG Ratio
−1.54−0.280.00
Price/Book
7.1x2.5x2.6x
Price / LTM Sales
11.1x3.7x3.2x
Upside (Analyst Target)
50.1%20.3%45.7%
Fair Value Upside
Unlock10.3%8.6%Unlock

Analyst Ratings

9 Buy
3 Hold
0 Sell
Ratings:
12 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 75.78
(+51.68% Upside)

Earnings

Latest Release
May 02, 2025
EPS / Forecast
-0.45 / -0.4907
Revenue / Forecast
69.16M / 65.43M
EPS Revisions
Last 90 days

PRCT Income Statement

People Also Watch

131.10
ALAB
-4.12%
5.5100
EOSE
-3.33%
44.810
RKLB
-2.42%
13.58
OSCR
-3.35%
54.89
TEM
-3.00%

FAQ

What Stock Exchange Does Procept Biorobotics Trade On?

Procept Biorobotics is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Procept Biorobotics?

The stock symbol for Procept Biorobotics is "PRCT."

What Is the Procept Biorobotics Market Cap?

As of today, Procept Biorobotics market cap is 2.76B.

What Is Procept Biorobotics's Earnings Per Share (TTM)?

The Procept Biorobotics EPS (TTM) is -1.70.

When Is the Next Procept Biorobotics Earnings Date?

Procept Biorobotics will release its next earnings report on 29 Oct 2025.

From a Technical Analysis Perspective, Is PRCT a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Procept Biorobotics Stock Split?

Procept Biorobotics has split 0 times.

How Many Employees Does Procept Biorobotics Have?

Procept Biorobotics has 756 employees.

What is the current trading status of Procept Biorobotics (PRCT)?

As of 02 Aug 2025, Procept Biorobotics (PRCT) is trading at a price of 49.96, with a previous close of 48.51. The stock has fluctuated within a day range of 47.13 to 49.99, while its 52-week range spans from 47.04 to 103.81.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.